JS212 Combination Therapies in Metastatic Colorectal Cancer

NCT07503756 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: JS212
DRUG: Capecitabine
DRUG: Bevacizumab
DRUG: Oxaliplatin
DRUG: JS207

Sponsor

Shanghai Junshi Bioscience Co., Ltd.